Elanco (ELAN) Stock
Key stats
- Market cap
- $13.24B
- Price / Earnings ratio
- -91.0x
- EPS (TTM)
- -$0.30
- Volume
- Loading
- 52-week high
- $27.98
- 52-week low
- $19.40
Source: third-party data provider, as of November 13, 2026
Compare with ELAN
Recent news

Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ELAN

Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
ELAN

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
ELAN

Elanco Director Purchases 40,000 Shares for $936,000
Elanco Director Purchases 40,000 Shares for $936,000
ELAN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 66.40
- MACD 12/26/9
- 0.89
- EMA 9 of MACD
- 0.50
- MACD histogram
- 0.39
- SMA 50
- $23.29
- Price above SMA 50
- EMA 50
- $23.75
- Price above EMA 50
- SMA 200
- $23.83
- Price above SMA 200
- EMA 200
- $23.56
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.19 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ELAN

Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
ELAN

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
ELAN

Elanco Director Purchases 40,000 Shares for $936,000
Elanco Director Purchases 40,000 Shares for $936,000
ELAN

Director's Confidence Visible as Elanco Leader Buys 10,000 Shares
Director's Confidence Visible as Elanco Leader Buys 10,000 Shares
ELAN

Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health Q2 Earnings Call Highlights
ELAN

Elanco CEO on Boosted Forecast, Surge in Tick Bites
Elanco CEO on Boosted Forecast, Surge in Tick Bites
ELAN

ADUS vs. ELAN: Which Stock Is the Better Value Option?
ADUS vs. ELAN: Which Stock Is the Better Value Option?
ELAN

Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say
Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say
ELAN

Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates
ELAN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Elanco
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jeffrey N. Simmons | President, CEO & Director | 1967 |
| Mr. Robert M. VanHimbergen | Executive VP & CFO | 1976 |
| Dr. Ramiro Martin Cabral | Executive VP & President of Elanco International | 1972 |
| Dr. Ellen de Brabander Ph.D. | Executive Vice President of Research, Development & Regulatory Affairs | 1963 |
| Mr. Timothy J. Bettington | Executive Vice President of Center of Strategic Growth | 1974 |
| Mr. James M. Meer | Senior VP & Chief Accounting Officer | 1970 |
| Mr. David S. Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration | 1967 |
| Ms. Shiv O'Neill | Executive Vice President, General Counsel & Corporate Secretary | 1975 |
| Mr. Larbi Van Lier | Senior Vice President of Asia | — |
| Prof. Shabbir Simjee | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 66.40
- MACD 12/26/9
- 0.89
- EMA 9 of MACD
- 0.50
- MACD histogram
- 0.39
- SMA 50
- $23.29
- Price above SMA 50
- EMA 50
- $23.75
- Price above EMA 50
- SMA 200
- $23.83
- Price above SMA 200
- EMA 200
- $23.56
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $24.00
- Average
- $29.00
- High
- $35.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.6 | +0.9 | ||||||||||
| 2022 | -7.8 | +11.2 | -9.8 | -3.1 | -5.8 | -18.6 | -1.7 | -22.9 | -19.3 | +5.0 | -3.1 | -7.4 |
| 2023 | +11.2 | -18.4 | -16.5 | +2.4 | -15.1 | +17.0 | +20.3 | +1.9 | -9.3 | -19.6 | +36.5 | +20.2 |
| 2024 | +0.7 | +7.4 | +1.6 | -17.6 | +34.4 | -18.7 | -7.5 | +18.6 | -3.0 | -12.8 | +4.8 | -10.2 |
| 2025 | -0.2 | -4.7 | -7.2 | -8.4 | +41.9 | +6.4 | -5.2 | +33.1 | +12.8 | +6.5 | +1.8 | +0.0 |
| 2026 | +6.9 | +6.7 | -8.3 | -3.2 | +6.0 | +4.0 | +9.5 | -7.0 | -6.4 | +5.9 | +9.9 |



